Geode Capital Management
HTGM

Geode Capital Management’s HTG Molecular Diagnostics, Inc. Common Stock HTGM Stock Holding History

Geode Capital Management’s Portfolio HTGM Stock Details HTGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,932
Closed -$28K – 4983
2022
Q3 		$28K Hold
3,932
– – ﹤0.01% 4862
2022
Q2 		$48K Buy
3,932
+95
+2% +$891 ﹤0.01% 4783
2022
Q1 		$63K Hold
3,837
– – ﹤0.01% 4767
2021
Q4 		$249K Hold
3,837
– – ﹤0.01% 4387
2021
Q3 		$262K Sell
3,837
-91
-2% -$6.51K ﹤0.01% 4329
2021
Q2 		$273K Buy
3,928
+1,009
+35% +$54.6K ﹤0.01% 4204
2021
Q1 		$191K Hold
2,919
– – ﹤0.01% 4126
2020
Q4 		$167K Buy
2,919
+777
+36% +$45.2K ﹤0.01% 3931
2020
Q3 		$127K Hold
2,142
– – ﹤0.01% 3849
2020
Q2 		$277K Hold
2,142
– – ﹤0.01% 3567
2020
Q1 		$125K Hold
2,142
– – ﹤0.01% 3692
2019
Q4 		$270K Buy
2,142
+788
+58% +$107K ﹤0.01% 3706
2019
Q3 		$165K Hold
1,354
– – ﹤0.01% 3842
2019
Q2 		$404K Buy
1,354
+29
+2% +$12.1K ﹤0.01% 3541
2019
Q1 		$596K Buy
1,325
+114
+9% +$49.9K ﹤0.01% 3366
2018
Q4 		$553K Buy
1,211
+158
+15% +$97.9K ﹤0.01% 3338
2018
Q3 		$956K Hold
1,053
– – ﹤0.01% 3241
2018
Q2 		$617K Buy
1,053
+40
+4% +$26.1K ﹤0.01% 3365
2018
Q1 		$660K Buy
1,013
+903
+821% +$678K ﹤0.01% 3299
2017
Q4 		$40K Hold
110
– – ﹤0.01% 3948
2017
Q3 		$33K Hold
110
– – ﹤0.01% 3979
2017
Q2 		$52K Hold
110
– – ﹤0.01% 3953
2017
Q1 		$137K Hold
110
– – ﹤0.01% 3764
2016
Q4 		$44K Hold
110
– – ﹤0.01% 3932
2016
Q3 		$46K Hold
110
– – ﹤0.01% 3924
2016
Q2 		$51K Hold
110
– – ﹤0.01% 3923
2016
Q1 		$56 Hold
110
– – ﹤0.01% 3953
2015
Q4 		$86K Hold
110
– – ﹤0.01% 3919
2015
Q3 		$151K Buy
+110
New +$170K ﹤0.01% 3775

Other funds holding HTGM

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HWM
HighMark Wealth Management St. Paul, Minnesota $246M AUM 35.95% 1-Year Est. Return
AF
Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TWA
TCI Wealth Advisors Tucson, Arizona $1.88B AUM 21.09% 1-Year Est. Return

Geode Capital Management's HTGM Position: Q4 2022 in Review

Geode Capital Management sold out of HTG Molecular Diagnostics, Inc. Common Stock (HTGM) in Q4 2022, closing a stake of 3,932 shares — an estimated $28K sold.

Geode Capital Management first reported a position in HTGM in Q3 2015 and held it in 29 quarters. The position peaked at $956K in Q3 2018. 10 funds tracked by Wall St. Rank hold HTGM as of Q4 2022.

  • Geode Capital Management reported no remaining HTG Molecular Diagnostics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Geode Capital Management sold 3,932 HTG Molecular Diagnostics, Inc. Common Stock shares in Q4 2022, an estimated $28K.
  • Geode Capital Management first reported a position in HTG Molecular Diagnostics, Inc. Common Stock in Q3 2015 and held it in 29 quarters.
  • Geode Capital Management's HTG Molecular Diagnostics, Inc. Common Stock position peaked at $956K in Q3 2018.
  • 10 funds tracked by Wall St. Rank held HTG Molecular Diagnostics, Inc. Common Stock as of Q4 2022.

Based on Geode Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.